Orthocell’s breakthrough product for peripheral nerve repair, Remplir™, has now gained Australian reimbursement – inclusion on the Australian Prostheses List – which is an important step in providing efficient and affordable access to this device.
Remplir™ was recently cleared for use in Australia by the TGA and an exclusive AU/NZ distributor appointed, Device Technologies.
Australia represents a significant addressable market, with 11,780 surgical repairs of peripheral nerves completed in the 2019/20 financial year, and Orthocell is now ideally positioned to expand its reach into the US, the largest global healthcare market in the world.